STATUS DECISION OF CONTROLLED AND NON-CONTROLLED SUBSTANCE(S)

Substance: 25H-NBOMe imine analog

Based on the current information available to the Office of Controlled Substances, it appears that the above substance is:

Controlled ☐
Not Controlled ✔

under the schedules of the Controlled Drugs and Substances Act (CDSA) for the following reason(s):

- The substance is not structurally similar to any of those listed in the CDSA.

Prepared by: ___________________________ Date: ______________
Vincent Marleau

Verified by: ___________________________ Date: ______________
Mark Kozlowski

Approved by: ___________________________ Date: ______________
DIRECTOR, OFFICE OF CONTROLLED SUBSTANCES

This status was requested by: Bruno Lafontaine, OCS
Drug: 25H-NBOMe imine analog

Drug Name Status: 25H-NBOMe imine analog is the common name.

Chemical Name: (E)-2-(2,5-dimethoxyphenyl)-N-(2-methoxybenzylidene)ethanamine

Chemical structure:

![Chemical Structure Image]

Molecular Formula: \( C_{18}H_{21}NO_3 \)

Pharmacological class / Application: Hallucinogen

CAS-RN: N/A

International status:

US: 25H-NBOMe imine analog is not listed specifically in the Schedules to the US Controlled Substances Act and is not mentioned anywhere on the DEA website.

United Nations: The substance is not listed on the Yellow List - List of Narcotic Drugs under International Control, the Green List - List of Psychotropic Substances under International Control, nor the Red List - List of Precursors and Chemicals Frequently Used in the Illicit Manufacture of Narcotic Drugs and Psychotropic Substances under International Control.

Canadian Status: 25H-NBOMe imine analog is not listed in the Schedules to the CDSA. The substance belongs to the family of designer phenethylamine derivatives which were originally synthesized by Shulgin and tested for their hallucinogenic potential. Currently, the only phenethylamine listed in the CDSA is 2C-B which is listed as item 24 “4-bromo-2,5-dimethoxybenzeneethanamine and any salt, isomer or salt of isomer thereof” in Schedule III to the CDSA. Since the analogues and derivatives of 2C-B are not captured by the item heading, 25H-NBOMe imine analog cannot be included under item 24 of Schedule III to the CDSA.

Recommendation: 25H-NBOMe imine analog is not included in the schedules to the CDSA and is not a controlled substance.

Date: October 29th, 2012.